Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study-Reference-Cited by-同舟云学术

Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study

Published:2021-05-03 Issue:8 Volume:23 Page:1823-1833
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Khunti Kamlesh¹^ORCID,Charbonnel Bernard²,Cooper Andrew³,Gomes Marília B.⁴^ORCID,Ji Linong⁵^ORCID,Leigh Paul³,Nicolucci Antonio⁶^ORCID,Rathmann Wolfgang⁷^ORCID,Shestakova Marina V.⁸,Siddiqui Afrah³,Tang Fengming⁹,Watada Hirotaka¹⁰^ORCID,Chen Hungta¹¹,

Affiliation:

1. University of Leicester Leicester UK

2. University of Nantes Nantes France

3. AstraZeneca Cambridge UK

4. Rio de Janeiro State University Rio de Janeiro Brazil

5. Peking University People's Hospital Beijing China

6. Center for Outcomes Research and Clinical Epidemiology Pescara Italy

7. Institute for Biometrics and Epidemiology, German Diabetes Center Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf Germany

8. Endocrinology Research Center Diabetes Institute Moscow Russian Federation

9. Saint Luke's Mid America Heart Institute Kansas City Missouri USA

10. Graduate School of Medicine Juntendo University Tokyo Japan

11. AstraZeneca Gaithersburg Maryland USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14400

Reference32 articles.

1. International Diabetes Federation. Global guideline for type 2 diabetes 2012.https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes. Accessed September 21 2020.

2. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme

4. Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!

5. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists;Diabetes and Vascular Disease Research;2024-07

2. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data;BMJ;2024-05-08

3. Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study;Biomedicines;2023-09-04

4. Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial;BMJ Medicine;2023-08

5. Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence;Diabetes, Obesity and Metabolism;2023-01-11